Oslo, Norway 15 April 2026 – the Board of Directors of Circio Holding ASA today approved the Company’s Remuneration Report and Annual Report, including the financial statements for 2025, which will be subject to approval by the Company’s Annual General Meeting (AGM) to be held on 8 May 2026.
The 2025 Remuneration Report and 2025 Annual Report (including the Auditors Report) and the version of the Annual Report in the European Single Electronic Format (ESEF) are attached to this press release and will be made available on the Company’s website.
The Annual Report including ESEF: https://www.circio.com/en/financial-reports/
The Remuneration Report: https://www.circio.com/en/remuneration-principles/
“2025 was a truly transformative year for Circio, generating groundbreaking data on our circVec platform that led directly to our first collaboration with a global pharmaceutical company,” said Dr. Erik Digman Wiklund, CEO of Circio. “These important R&D and business development milestones enabled Circio to secure a substantial capital infusion in early 2026, and we can now accelerate the development of our circVec circular RNA-based expression technology with a cash runway into 2030. We already have an exciting pipeline of upcoming R&D milestones, which can now be scaled up with the aim of validating the circVec platform in new areas and creating novel business opportunities in the near to mid-term future.”